Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Safety in Lewy Body Disease Patients With Oxyhyperglycemia-Related Hypotension
jRCTs031190016Recruiting
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sitagliptin in Postprandial hypotension (PPH), orthostatic hypotension (OH), Lewy body dementia (LBD) and 3 more. Primary endpoint: Severe hypoglycemic events during sitagliptin treatment. Started Feb 2019; status: recruiting.
02
Drugs
sitagliptin
03
Conditions
Postprandial hypotension (PPH)orthostatic hypotension (OH)Lewy body dementia (LBD)Parkinson's disease (PD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on jRCTs031190016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190016.